摘要目的:探讨结外NK/T细胞淋巴瘤中pSTAT3和PD-L1表达及其与临床病理特征及预后的关系。方法:收集广东省人民医院2015年6月至2019年2月51例确诊为结外NK/T细胞淋巴瘤的病例，采用免疫组织化学方法，研究pSTAT3和PD-L1在结外NK/T细胞淋巴瘤的表达情况并进行统计学分析。结果:51例结外NK/T细胞淋巴瘤中，男性35例，女性16例，年龄范围为18~85岁，中位年龄47岁；pSTAT3阳性率为68.6%（35/51）；PD-L1阳性率为76.5%（39/51）；两者表达呈正相关（ P=0.033， R=0.322）。pSTAT3及PD-L1表达与各临床参数（包括年龄、性别、发病部位、有无B症状、Ann Arbor分期、乳酸脱氢酶值、外周血EB病毒DNA含量、国际预后指数评分）之间均无相关性（ P>0.05）。Kaplan-Meier生存分析显示pSTAT3和PD-L1阳性组预后分别略优于阴性组，但差异无统计学意义（ P>0.05）。 结论:pSTAT3在结外NK/T细胞淋巴瘤中高表达，并且与PD-L1表达具有相关性，为结外NK/T细胞淋巴瘤治疗提供了潜在靶点，并为STAT3靶向药物和免疫检查点抑制药物的联合使用提供了一定的理论依据。

abstractsObjective:To study the expression of phosphates signal transducer and activator of transcription 3 (pSTAT3) and programmed death ligand-1 (PD-L1) in extranodal NK/T cell lymphomas (ENKTCL) and the relationships of pSTAT3 and PD-L1 expression with the clinicopathological characteristics and prognosis of ENKTCL.Methods:Fifty-one cases of ENKTCL diagnosed at Guangdong Provincial People′s Hospital from June 2015 to February 2019 were included in the study. The expression of pSTAT3 and PD-L1 was examined using immunohistochemistry.Results:There were 35 males and 16 females, ranging from 18 to 85 years old with a median age of 47 years. The positive rates of pSTAT3 and PD-L1 expression were 68.6% (35/51) and 76.5% (39/51), respectively. pSTAT3 expression was correlated with PD-L1 expression ( P=0.033, R=0.322), while there were no associations of pSTAT3 and PD-L1 expression with the clinicopathological characteristics of ENKTCL, including age, sex, clinical site, B symptom, Ann Arbor stage, LDH value, EBV DNA load of peripheral blood and international proliferation index score. Kaplan-Meier survival analysis showed the prognoses of the pSTAT3 and PD-L1 positive groups were slightly better than the respective negative groups, but the differences were not significantly ( P>0.05). Conclusions:pSTAT3 is highly expressed in extranodal NK/T cell lymphoma and related to the expression of PD-L1, which provides a potential target and rationale for combinations of targeted therapies and immune checkpoint blockade inhibitors in the treatment of ENKTCL.